Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Phys Rev Lett ; 110(5): 053902, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-23414021

ABSTRACT

We demonstrate ultrafast delay tuning of a slow-light pulse with a response time <10 ps. This is achieved using two types of slow light: dispersion-compensated slow light for the signal pulse, and low-dispersion slow light to enhance nonlinear effects of the control pulse. These two types of slow light are generated simultaneously in Si lattice-shifted photonic crystal waveguides, arising from flat and straight photonic bands, respectively. The control pulse blueshifts the signal pulse spectrum, through dynamic tuning caused by the plasma effect of two-photon-absorption-induced carriers. This changes the delay by up to 10 ps only when the two pulses overlap within the waveguide and enables ultrafast tuning that is not limited by the carrier lifetime. Using this, we succeeded in tuning the delay of one target pulse within a pulse train with 12 ps intervals.

2.
J Dent Res ; 99(7): 830-838, 2020 07.
Article in English | MEDLINE | ID: mdl-32202959

ABSTRACT

Interleukin-1ß (IL-1ß) is an inflammatory cytokine produced by monocytes/macrophages and is closely associated with periodontal diseases. The NLRP3 inflammasome is involved in IL-1ß activation through pro-IL-1ß processing and pyroptotic cell death in bacterial infection. Recently, glyburide, a hypoglycemic sulfonylurea, has been reported to reduce IL-1ß activation by suppressing activation of the NLRP3 inflammasome. Therefore, we evaluated the possibility of targeting the NLRP3 inflammasome pathway by glyburide to suppress periodontal pathogen-induced inflammation. THP-1 cells (a human monocyte cell line) were differentiated to macrophage-like cells by treatment with phorbol 12-myristate 13-acetate and stimulated by periodontopathic bacteria, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, or Fusobacterium nucleatum, in the presence of glyburide. IL-1ß and caspase-1 expression in the cells and culture supernatants were analyzed by Western blotting and enzyme-linked immunosorbent assay, and cell death was analyzed by lactate dehydrogenase assay. Stimulation of THP-1 macrophage-like cells with every periodontopathic bacteria induced IL-1ß secretion without cell death, which was suppressed by the NLRP3 inhibitor, MCC950, and caspase-1 inhibitor, z-YVAD-FMK. Glyburide treatment suppressed IL-1ß expression in culture supernatants and enhanced intracellular IL-1ß expression, suggesting that glyburide may have inhibited IL-1ß secretion. Subsequently, a periodontitis rat model was generated by injecting periodontal bacteria into the gingiva, which was analyzed histologically. Oral administration of glyburide significantly suppressed the infiltration of inflammatory cells and the number of osteoclasts in the alveolar bone compared with the control. In addition to glyburide, glimepiride was shown to suppress the release of IL-1ß from THP-1 macrophage-like cells, whereas other sulfonylureas (tolbutamide and gliclazide) or other hypoglycemic drugs belonging to the biguanide family, such as metformin, failed to suppress IL-1ß release. Our results suggest that pharmacological targeting of the NLRP3 pathway may be a strategy for suppressing periodontal diseases.


Subject(s)
Inflammation , Animals , Caspase 1 , Inflammasomes , Inflammation/drug therapy , Interleukin-1beta , Monocytes , NLR Family, Pyrin Domain-Containing 3 Protein , Periodontitis , Rats
3.
Cancer Res ; 52(16): 4514-21, 1992 Aug 15.
Article in English | MEDLINE | ID: mdl-1643643

ABSTRACT

To investigate the role of protein kinase C (PKC) in the 12-O-tetradecanoylphorbol-13-acetate (TPA)-dependent growth of human melanocytes, we analyzed the effects of phorbol ester treatment on both PKC expression and growth control in these cells. We found that established cultures of normal melanocytes contain the PKC alpha, PKC beta, and PKC epsilon isoforms. The abilities of various phorbol ester compounds to stimulate DNA synthesis in these cultured melanocytes correlated with their known potencies for activation of PKC and tumor promotion. Dose-response studies revealed that the most effective TPA concentration for stimulation of DNA synthesis and growth of melanocytes (10 ng/ml TPA) also supported a relatively high level of PKC enzyme activity, increased membrane association of the PKC alpha and PKC epsilon isoforms, and led to a high level of phosphorylation of a major PKC substrate, the myristoylated alanine-rich C kinase substrate (MARCKS) protein. Melanocytes incubated for 48 h with TPA at a higher concentration (100 ng/ml TPA) exhibited suboptimal TPA-stimulated DNA synthesis (28% of maximal) and decreased phosphorylation of the MARCKS substrate protein (50% of maximal). Furthermore, treatment of melanocytes with 100 ng/ml TPA for 48 h resulted in a marked decrease in total PKC enzyme activity and the loss of expression of the PKC alpha and PKC epsilon isoforms in both the cytosol and membrane-bound fractions, when examined by immunoblot analysis. These results, taken together, suggest that continuous activation of PKC by TPA, rather than the loss of PKC due to TPA-induced down-regulation, is responsible for the growth-stimulatory effects of phorbol esters on normal human melanocytes. Additionally, the conditioned medium from TPA-treated human melanocytes stimulated DNA synthesis in quiescent melanocytes and human melanoma cells, thus suggesting that activation of the PKC signaling pathway in melanocytes leads to the production of an autocrine growth factor. These findings may be relevant to the autonomous growth of malignant melanomas.


Subject(s)
DNA/biosynthesis , Intracellular Signaling Peptides and Proteins , Isoenzymes/metabolism , Melanocytes/cytology , Membrane Proteins , Protein Kinase C/metabolism , Proteins/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Cell Division/drug effects , Cells, Cultured , Culture Media, Serum-Free/chemistry , Culture Media, Serum-Free/pharmacology , Dose-Response Relationship, Drug , Enzyme Activation , Humans , Isoenzymes/chemistry , Melanocytes/drug effects , Melanocytes/metabolism , Molecular Weight , Myristoylated Alanine-Rich C Kinase Substrate , Phosphorylation , Protein Kinase C/chemistry , Proteins/chemistry , Time Factors
4.
Cancer Res ; 48(17): 4959-63, 1988 Sep 01.
Article in English | MEDLINE | ID: mdl-3261629

ABSTRACT

A new T-cell lymphoma cell line, designated T34, was established from freshly isolated lymph node tumor cells of a patient with non-Hodgkin's diffuse large cell lymphoma. The T34 cells, as well as the parental lymphoma cells, showed mature helper/inducer immunophenotypes in that they formed spontaneous sheep erythrocyte rosettes and reacted with OKT-3 and OKT-4 monoclonal antibodies. They were negative for OKT-6, OKT-8, terminal deoxynucleotidyl transferase, WT-1, and HLA-DR antigens. Molecular analysis revealed that the T34 cells contained 8- to 16-fold amplified c-myc DNA. The same genetic change was observed in parental lymphoma cells, indicating that the c-myc amplification had occurred in vivo. There was no gross rearrangement of the c-myc DNA. The c-myc gene of the T34 cell line was actively transcribed into normal-sized c-myc mRNA. Cytogenetic analysis showed that both the T34 and the parental lymphoma cells had a near-triploid karyotype with multiple structural chromosome changes. The terminal end of the long arm of chromosome No. 8, the chromosomal locus of single-copy c-myc, was elongated (8q+ chromosome), perhaps reflecting the site of c-myc amplification. These data suggested that amplification of the c-myc oncogene played some role in progression and proliferation of this peripheral T-cell neoplasm.


Subject(s)
Gene Amplification , Lymphoma/genetics , Proto-Oncogenes , Aged , Cell Differentiation , Chromosome Aberrations , DNA/analysis , Humans , Lymphoma/pathology , Male , T-Lymphocytes , Transcription, Genetic , Tumor Cells, Cultured
5.
Cancer Res ; 46(12 Pt 1): 6400-5, 1986 Dec.
Article in English | MEDLINE | ID: mdl-3465438

ABSTRACT

The YK-M2 cell line was established from the peripheral blood of a patient with acute monoblastic leukemia in whom an anterior mediastinal tumor preceded the peripheral blood manifestation. The established cells grew in a single cell suspension with a doubling time of 60 h and consisted of primitive monoblastic cells. The cells were 52% positive for peroxidase staining and manifested strongly positive activity of alpha-naphthyl acetate esterase, which was completely inhibited by sodium fluoride. The cells showed strong expression of Fc gamma receptors and phagocytosed sensitized ox erythrocytes. When the cells were incubated with 1 alpha,25-dihydroxy-vitamin D3, they were induced to differentiate into mature monocyte-macrophage-like cells, which reduced the nitroblue tetrazolium dye and released a small amount of the superoxide anion. Cytogenetic studies revealed that the cells had a near-triploid karyotype with a modal chromosome number of 68, and the short arm of one No. 17 chromosome was deleted [del(17)(p11)]. The YK-M2 cell line is particularly unique in that the cells retained the polyploid karyotype that may be an initial cytogenetic change in the malignant transformation of the parent leukemia cells.


Subject(s)
Chromosome Aberrations , Leukemia, Monocytic, Acute/genetics , Polyploidy , Adult , Calcitriol/pharmacology , Cell Differentiation/drug effects , Cell Line , Humans , Karyotyping , Leukemia, Monocytic, Acute/immunology , Leukemia, Monocytic, Acute/pathology , Male
6.
Circulation ; 103(8): 1057-63, 2001 Feb 27.
Article in English | MEDLINE | ID: mdl-11222466

ABSTRACT

BACKGROUND: Excessive lipid accumulation in macrophages plays an important role in the development of atherosclerosis. Recently, we discovered an adipocyte-specific plasma protein, adiponectin, that is decreased in patients with coronary artery disease. We previously demonstrated that adiponectin acts as a modulator for proinflammatory stimuli and inhibits monocyte adhesion to endothelial cells. The present study investigated the effects of adiponectin on lipid accumulation in human monocyte-derived macrophages. METHODS AND RESULTS: Human monocytes were differentiated into macrophages by incubation in human type AB serum for 7 days, and the effects of adiponectin were investigated at different time intervals. Treatment with physiological concentrations of adiponectin reduced intracellular cholesteryl ester content, as determined using the enzymatic, fluorometric method. The adiponectin-treated macrophages contained fewer lipid droplets stained by oil red O. Adiponectin suppressed the expression of the class A macrophage scavenger receptor (MSR) at both mRNA and protein levels by Northern and immunoblot analyses, respectively, without affecting the expression of CD36, which was quantified by flow cytometry. Adiponectin reduced the class A MSR promoter activity, as measured by luciferase reporter assay. Adiponectin treatment dose-dependently decreased class A MSR ligand binding and uptake activities. The mRNA level of lipoprotein lipase as a marker of macrophage differentiation was decreased by adiponectin treatment, but that of apolipoprotein E was not altered. Adiponectin was detected around macrophages in the human injured aorta by immunohistochemistry. CONCLUSIONS: The adipocyte-derived plasma protein adiponectin suppressed macrophage-to-foam cell transformation, suggesting that adiponectin may act as a modulator for macrophage-to-foam cell transformation.


Subject(s)
Adipocytes/chemistry , Intercellular Signaling Peptides and Proteins , Lipid Metabolism , Macrophages/drug effects , Proteins/pharmacology , Receptors, Immunologic/biosynthesis , Adiponectin , Apolipoproteins E/genetics , Apolipoproteins E/metabolism , Blood Proteins/pharmacology , CD36 Antigens/metabolism , Cell Differentiation/drug effects , Cells, Cultured , Cholesterol Esters/metabolism , Foam Cells/cytology , Foam Cells/drug effects , Humans , Lipoprotein Lipase/genetics , Lipoprotein Lipase/metabolism , Lipoproteins, LDL/metabolism , Macrophages/metabolism , Monocytes/cytology , Peptide Fragments/genetics , Peptide Fragments/metabolism , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Receptors, Scavenger , Scavenger Receptors, Class A
7.
Circulation ; 102(11): 1296-301, 2000 Sep 12.
Article in English | MEDLINE | ID: mdl-10982546

ABSTRACT

BACKGROUND: Among the many adipocyte-derived endocrine factors, we found an adipocyte-derived plasma protein, adiponectin, that was decreased in obesity. We recently demonstrated that adiponectin inhibited tumor necrosis factor-alpha (TNF-alpha)-induced expression of endothelial adhesion molecules and that plasma adiponectin level was reduced in patients with coronary artery disease (CIRCULATION: 1999;100:2473-2476). However, the intracellular signal by which adiponectin suppressed adhesion molecule expression was not elucidated. The present study investigated the mechanism of modulation for endothelial function by adiponectin. METHODS AND RESULTS: The interaction between adiponectin and human aortic endothelial cells (HAECs) was estimated by cell ELISA using biotinylated adiponectin. HAECs were preincubated for 18 hours with 50 microg/mL of adiponectin, then exposed to TNF-alpha (10 U/mL) or vehicle for the times indicated. NF-kappaB-DNA binding activity was determined by electrophoretic mobility shift assays. TNF-alpha-inducible phosphorylation signals were detected by immunoblotting. Adiponectin specifically bound to HAECs in a saturable manner and inhibited TNF-alpha-induced mRNA expression of monocyte adhesion molecules without affecting the interaction between TNF-alpha and its receptors. Adiponectin suppressed TNF-alpha-induced IkappaB-alpha phosphorylation and subsequent NF-kappaB activation without affecting other TNF-alpha-mediated phosphorylation signals, including Jun N-terminal kinase, p38 kinase, and Akt kinase. This inhibitory effect of adiponectin is accompanied by cAMP accumulation and is blocked by either adenylate cyclase inhibitor or protein kinase A (PKA) inhibitor. CONCLUSIONS: These observations raise the possibility that adiponectin, which is naturally present in the blood stream, modulates the inflammatory response of endothelial cells through cross talk between cAMP-PKA and NF-kappaB signaling pathways.


Subject(s)
Adipose Tissue/metabolism , Cyclic AMP/physiology , Endothelium, Vascular/metabolism , I-kappa B Proteins , Intercellular Signaling Peptides and Proteins , NF-kappa B/physiology , Proteins/physiology , Adenylyl Cyclase Inhibitors , Adiponectin , Aorta/cytology , Biotinylation , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Cyclic AMP/biosynthesis , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , DNA-Binding Proteins/metabolism , Electrophoresis/methods , Endothelium, Vascular/cytology , Enzyme Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay , Humans , Immunoblotting , In Vitro Techniques , Monocytes/metabolism , NF-KappaB Inhibitor alpha , NF-kappa B/metabolism , Phosphorylation , Protein Binding , Proteins/metabolism , RNA, Messenger/metabolism , Tumor Necrosis Factor-alpha/pharmacology
8.
Diabetes ; 50(5): 1126-33, 2001 May.
Article in English | MEDLINE | ID: mdl-11334417

ABSTRACT

Adiponectin is an adipose-specific plasma protein whose plasma concentrations are decreased in obese subjects and type 2 diabetic patients. This protein possesses putative antiatherogenic and anti-inflammatory properties. In the current study, we have analyzed the relationship between adiponectin and insulin resistance in rhesus monkeys (Macaca mulatta), which spontaneously develop obesity and which subsequently frequently progress to overt type 2 diabetes. The plasma levels of adiponectin were decreased in obese and diabetic monkeys as in humans. Prospective longitudinal studies revealed that the plasma levels of adiponectin declined at an early phase of obesity and remained decreased after the development of type 2 diabetes. Hyperinsulinemic-euglycemic clamp studies revealed that the obese monkeys with lower plasma adiponectin showed significantly lower insulin-stimulated peripheral glucose uptake (M rate). The plasma levels of adiponectin were significantly correlated to M rate (r = 0.66, P < 0.001). Longitudinally, the plasma adiponectin decreased in parallel to the progression of insulin resistance. No clear association was found between the plasma levels of adiponectin and its mRNA levels in adipose tissue. These results suggest that reduction in circulating adiponectin may be related to the development of insulin resistance.


Subject(s)
Diabetes Mellitus, Type 2/veterinary , Diabetes Mellitus/veterinary , Intercellular Signaling Peptides and Proteins , Obesity/veterinary , Primate Diseases/physiopathology , Proteins/metabolism , Adiponectin , Adipose Tissue/anatomy & histology , Amino Acid Sequence , Animals , Blood Glucose/metabolism , Body Weight , Diabetes Mellitus/blood , Diabetes Mellitus/physiopathology , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/physiopathology , Disease Progression , Glucose Clamp Technique , Humans , Hyperinsulinism/blood , Insulin/administration & dosage , Insulin/pharmacology , Leptin/blood , Leptin/genetics , Macaca mulatta , Male , Molecular Sequence Data , Obesity/blood , Obesity/physiopathology , Organ Size , Primate Diseases/blood , Proteins/chemistry , Proteins/genetics , Sequence Alignment , Sequence Homology, Amino Acid
9.
Cell Signal ; 8(7): 487-96, 1996 Nov.
Article in English | MEDLINE | ID: mdl-9023013

ABSTRACT

This study was performed to evaluate the effect of human recombinant basic fibroblast growth factor on arachidonic acid release from rat pancreatic acini and to determine the cellular mechanism involved. From enzymatic assays, basic fibroblast growth factor did not significantly stimulate phospholipase A2 activity, whereas it significantly increased diacylglycerol lipase activity. Validity of phospholipase A2 or diacylglycerol lipase inhibitors was confirmed by their ability to inhibit phospholipase A2 or diacylglycerol lipase activities. Basic fibroblast growth factor increased intracellular accumulation and extracellular release of arachidonic acid from metabolically labelled acinar cells in a concentration- and time-dependent manner. This effect was maximal with 50 pM basic fibroblast growth factor and became significant after a 5-min incubation period. The protein tyrosine kinase inhibitor, 0.5 mM genistein, inhibited arachidonic acid release in basic fibroblast growth factor-stimulated acini, whereas 100 microM vanadate, a protein tyrosine phosphatase inhibitor, enhanced arachidonic acid release. Two phospholipase A2 inhibitors, mepacrine and aristolochic acid, failed to attenuate basic fibroblast growth factor-stimulated arachidonic acid release. A diacylglycerol lipase inhibitor RHC 80267 at 150 microM and 50 microM completely inhibited 50 pM basic fibroblast growth factor-induced intracellular accumulation and extracellular release of arachidonic acid, respectively. Furthermore, basic fibroblast growth factor stimulated arachidonic acid release was also inhibited by 10 microM U73122 and by 100 nM staurosporine, phospholipase C and protein kinase C respective inhibitors. Wortmannin, an inhibitor of basic fibroblast growth factor-stimulated phospholipase D, did not affect arachidonic acid release. 100 nM 4 beta-phorbol 12-myristate 13-acetate also increased arachidonic acid release, an effect also inhibited by staurosporine. Taken together, these data demonstrate activation of diacylglycerol lipase and arachidonic acid release in pancreatic acini upon stimulation by basic fibroblast growth factor, and strongly indicate that arachidonic acid release in response to basic fibroblast growth factor depends upon the sequential action of tyrosine kinase, phospholipase C, protein kinase C and diacylglycerol lipase but not from phospholipase A2 not phospholipase D activation.


Subject(s)
Arachidonic Acid/metabolism , Fibroblast Growth Factor 2/metabolism , Glycerophospholipids , Lipoprotein Lipase/metabolism , Pancreas/metabolism , Protein Kinase C/metabolism , Protein-Tyrosine Kinases/metabolism , Type C Phospholipases/metabolism , Animals , Arachidonic Acid/pharmacokinetics , Cells, Cultured , Enzyme Activation , Humans , Male , Pancreas/cytology , Phosphatidic Acids/analysis , Phospholipase D/metabolism , Phospholipases A/analysis , Phospholipases A2 , Rats , Rats, Sprague-Dawley , Time Factors , Tritium/pharmacokinetics
10.
J Invest Dermatol ; 100(6): 812-5, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8496621

ABSTRACT

Patients with vitiligo have been found to have circulating antibodies to pigment cells. To evaluate the functional activity of these antibodies, a highly sensitive europium release assay was used to compare complement-mediated cytolysis of human melanocytes by sera of 56 patients with vitiligo (20 with active disease, 25 with inactive disease, 11 with unidentified disease activity) and 47 control individuals. Significant melanocyte lysis was mediated by 32 (57%) of the patients with vitiligo but by only three (6%) of the control sera (p < 0.001), and by 17 (85%) of 20 patients with active vitiligo versus 11 (44%) of 25 patients with inactive disease (p < 0.025). Mean melanocyte lysis by vitiligo sera was 24% versus 6% by control sera (p < 0.0001). A subset of 12 vitiligo sera with high titers of cytolytic antibodies to melanocytes (34% mean cytolysis) reacted minimally (< 2% mean cytolysis) to a panel of control cells that included human and murine melanomas, human fibroblasts, lung carcinoma, and rhabdomyosarcoma. These findings indicate that antibodies present in patients with vitiligo have the functional ability to selectively kill melanocytes and are more common in active disease. These observations support, but do not prove, the hypothesis that vitiligo is an autoimmune disease and that anti-pigment cell antibodies have a role in inducing the disease.


Subject(s)
Antibodies/immunology , Melanocytes/immunology , Vitiligo/immunology , Antibodies/blood , Antibody Specificity , Cytotoxicity, Immunologic , Europium/metabolism , Humans , Methods , Severity of Illness Index , Vitiligo/blood , Vitiligo/pathology
11.
Am J Clin Pathol ; 91(2): 152-8, 1989 Feb.
Article in English | MEDLINE | ID: mdl-2464922

ABSTRACT

The authors immunohistochemically analyzed the phenotype of 40 cases of peripheral T-cell lymphoma, including 12 adult T-cell leukemia/lymphoma (ATL) cases. Molecular genetic analysis of the T-cell receptor beta-chain and immunoglobulin heavy chain genes were also applied to cases of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)-like lymphoma and so-called Lennert's lymphoma. Twenty non-ATL lymphomas expressed a helper/inducer phenotype, whereas only one extranodal case expressed a suppressor/cytotoxic phenotype. Three cases had a CD4-CD8- phenotype, and two cases a CD4+CD8+phenotype. No specific relationship between morphologic characteristics (LSG classification) and phenotype was found among non-ATL lymphomas. Six of eight AILD-like lymphomas had a helper/inducer phenotype. Monoclonality of neoplastic T-cells was demonstrated in six of the seven cases of AILD-like lymphoma by molecular genetic analysis. Two cases of Lennert's lymphoma also showed a helper/inducer phenotype and rearrangement of the T-cell receptor beta-chain gene. Serologically defined ATL cases had a helper/inducer phenotype except in one case that expressed both CD4 and CD8. None of the ATL cases had the CD7 antigen in this study using WT 1 as a CD7 antibody, which is in contrast with the non-ATL lymphomas in which 13 of 25 cases expressed CD7. CD25, strongly detectable in all ATL cases, was negative or weakly expressed in non-ATL lymphomas. These facts suggest that non-ATL and ATL are in the different biologic state, probably resulting from the integration of human T-cell leukemia virus type I (HTLV-I), although both are derived from helper/inducer T-cells.


Subject(s)
Lymphoma/pathology , Antigens, Differentiation, T-Lymphocyte/analysis , Humans , Immunohistochemistry , Leukemia-Lymphoma, Adult T-Cell/immunology , Leukemia-Lymphoma, Adult T-Cell/pathology , Lymphoma/diagnosis , Lymphoma/immunology , Phenotype , Staining and Labeling , T-Lymphocytes
12.
J Biochem ; 85(5): 1355-65, 1979 May.
Article in English | MEDLINE | ID: mdl-36376

ABSTRACT

NADP-linked malic enzyme [EC 1.1.1.40] was highly purified from Escherichia coli W cells. The purified enzyme was homogeneous as judged by ultracentrifugation and gel electrophoresis. The apparent molecular weights obtained by sedimentation equilibrium analysis, from diffusion and sedimentation constants, and by disc electrophoresis at various gel concentrations were 471,000, 438,000, and 495,000, respectively. The subunit molecular weights obtained by sedimentation equilibrium analysis in the presence of 6 M guanidine hydrochloride and gel electrophoresis in the presence of sodium dodecyl sulfate were 76,000 and 82,000, respectively. The sedimentation coefficient (S(0)20, W) was 13.8S, and the molecular activity was 44,700 min-1 at 30 degrees C. The amino acid composition of the enzyme was determined, and the results were compared with those of NAD-linked malic enzyme from the same organism and those of pigeon liver NADP-linked malic enzyme. The partial specific volume was calculated to be 0.738 ml/g. The Km value for L-malate was 2.3 mM at pH 7.4. Malonate, tartronate, glutarate, and DL-tartrate competitively inhibited the activity. The saturation profile for L-malate exhibited a marked cooperativity in the presence of both chloride ions and acetyl-CoA. However, acetyl-CoA alone did not show cooperativity or produce inhibition in the absence of chloride ions. Vmax and Km were determined as a function of pH. The optimum pH for the reaction was 7.8. Inspection of the Dixon plots suggested that three ionizable groups of the enzyme are essential for the enzyme activity. In addition to the oxidative decarboxylase activity, the enzyme preparation exhibited divalent metal ion-dependent oxaloacetate decarboxylase and alpha-keto acid reductase activities. Based on the above results, the molecular properties of the enzymatic reaction are discussed.


Subject(s)
Escherichia coli/enzymology , Malate Dehydrogenase/isolation & purification , Acetyl Coenzyme A/pharmacology , Amino Acids/analysis , Hydrogen-Ion Concentration , Kinetics , Malate Dehydrogenase/metabolism , Molecular Weight , NADP , Potassium Chloride/pharmacology
13.
J Biochem ; 109(1): 178-83, 1991 Jan.
Article in English | MEDLINE | ID: mdl-2016266

ABSTRACT

Glycoproteins which bound to Dolichos biflorus agglutinin (DBA) were isolated from the small intestine of 129/Sv mice. Among oligosaccharides released from the carbohydrate moieties of the glycoproteins by endo-beta-galactosidase, the major one with N-acetylgalactosamine at the non-reducing end was isolated by QAE-Sephadex A-25 column chromatography. The structure of the oligosaccharide was elucidated to be GalNAc beta 1----4(NeuAc alpha 2----3)Gal beta 1----4GlcNAc beta 1----3Gal by compositional analysis, methylation analysis before and after mild acid hydrolysis, sequential glycosidase digestion, secondary ion mass spectrometry (SIMS), and nuclear magnetic resonance spectroscopy. The SIMS signal of m/z 1,071 was consistent with the presence of the branched sequence, GalNAc(NeuAc)GalGlcNAc, and the signal was also detected in the high-molecular-weight fraction obtained after endo-beta-galactosidase digestion. The pentasaccharide identified here has the terminal structure of ganglioside GM2, and an apparently identical one has been identified as the epitope of blood group Sda and the DBA binding site in human T-H urinary glycoprotein. Thus, the present result has extended our knowledge of the biological meaning of the oligosaccharide structure and has established that GalNAc beta 1----4(NeuAc alpha 2----3)Gal beta 1----4GlcNAc is a DBA binding site in the small intestine of the mouse.


Subject(s)
Intestine, Small/metabolism , Lectins/metabolism , Plant Lectins , Animals , Binding Sites , Carbohydrate Sequence , Glycoproteins/metabolism , Mice , Molecular Sequence Data , Oligosaccharides/chemistry , Oligosaccharides/metabolism , Receptors, Mitogen/metabolism
14.
Int J Hematol ; 59(3): 211-8, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8011990

ABSTRACT

The t(14;19)(q32;q13) is a recurring translocation found in some patients with chronic lymphocytic leukemia (CLL), and the t(14;19) juxtaposes the BCL3 gene on chromosome 19 with the immunoglobulin heavy chain gene (IGH) locus on chromosome 14. Genomic DNAs from 49 patients with chronic B-cell leukemia and the related lymphomas were examined by Southern blot hybridization using 2 separate probes, named p alpha 1.4P and p alpha .5B, from the BCL3 gene locus. None of the 18 patients with leukemic manifestations of non-Hodgkin's lymphomas had detectable BCL3 rearrangements. Of 31 patients with CLL, 2 had the BCL3 rearrangements. A comigration study using the C alpha and C epsilon constant gene probe from IGH indicated that the t(14;19) translocation occurred in these 2 patients, and they were diagnosed with CLL/prolymphocytic (PL) according to the French-American-British (FAB) classification. Probes for the IGH locus revealed that leukemia cells of the 2 patients each were clonal, indicating that both small lymphocytes and prolymphocytoid cells found in the peripheral blood of one patient had the t(14;19), as well as a major population of the small lymphocytes in the peripheral blood of a second patient. It thus appears that tumor cells carrying the t(14;19) constitute a distinct disease entity in a group of chronic B-cell leukemia, that has a converting potential to more aggressive forms.


Subject(s)
Gene Rearrangement , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogenes , Aged , B-Cell Lymphoma 3 Protein , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 19 , Female , Humans , Male , Transcription Factors
15.
Pancreas ; 14(3): 301-8, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9094163

ABSTRACT

Recent studies have suggested the involvement of phospholipase A2 (PLA2) in pancreatic amylase secretion. The present study was designed to investigate the secretory role of arachidonic acid (AA) in carbachol (Cch)-stimulated rat pancreatic acini and its origin. From enzymatic assays, PLA2 and diacylglycerol (DAG) lipase were activated by Cch and respectively inhibited by the PLA2 inhibitors, mepacrine and aristolochic acid, and by the DAG lipase inhibitor, RHC 80267. Melittin-activated PLA2 activity was also inhibited by the PLA2 inhibitors. Cch-stimulated endogenous AA release from pancreatic acini was partially inhibited by 150 microM RHC 80267 and by 150 microM mepacrine or 200 microM aristolochic acid and totally inhibited by a combination of the two enzyme inhibitors. Exogenous AA caused amylase release in a concentration-dependent manner. Eicosatetraynoic acid (a cyclooxygenase and lipoxygenase inhibitor), significantly increased basal and Cch-induced AA release and amylase secretion. RHC 80267 and the PLA2 inhibitors separately and partially suppressed Cch-stimulated amylase secretion, with an additive effect observed when the DAG lipase and the PLA2 inhibitors were combined. A combination of RHC 80267, mepacrine, or aristolochic acid and the phospholipase C (PLC) inhibitor U73122 completely inhibited Cch-stimulated amylase secretion. Finally, the PLA2 activator melittin-stimulated amylase secretion was blocked by the two PLA2 inhibitors. We conclude that exogenous and endogenous AA can induce amylase secretion. Therefore, AA released from either PLC-DAG lipase or PLA2 pathways can be considered an additional and important intracellular mediator of amylase secretion.


Subject(s)
Amylases/metabolism , Arachidonic Acid/metabolism , Aristolochic Acids , Pancreas/metabolism , Animals , Arachidonic Acid/pharmacology , Carbachol/pharmacology , Cyclohexanones/pharmacology , Enzyme Inhibitors/pharmacology , In Vitro Techniques , Lipoprotein Lipase/antagonists & inhibitors , Lipoprotein Lipase/physiology , Male , Melitten/pharmacology , Pancreas/drug effects , Pancreas/enzymology , Phenanthrenes/pharmacology , Phospholipases A/antagonists & inhibitors , Phospholipases A/physiology , Phospholipases A2 , Quinacrine/pharmacology , Rats , Rats, Sprague-Dawley
16.
Pancreas ; 6(1): 112-9, 1991 Jan.
Article in English | MEDLINE | ID: mdl-1704630

ABSTRACT

Pretreatment of rat pancreatic acini with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) for 5 or 10 min reduced cytosolic free calcium and amylase secretion stimulated by submaximal concentration (10(-6) M) of carbachol in a dose-dependent manner. 10(-7) M TPA inhibited initial amylase secretion and had no effect on sustained secretion stimulated by 10(-6) M carbachol. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H7), a protein kinase C inhibitor, partially blocked these inhibitory effects of TPA. Cytosolic calcium concentration and initial amylase secretion were recovered with 10-100 microM H7 in TPA-treated acini. H7 was more effective than N-(2-guanidinoethyl)-5-isoquinoline-sulfonamide hydrochloride in increasing cytosolic free calcium in TPA-treated acini. TPA completely blocked an increase in cytosolic free calcium by 10 mM NaF. These findings indicated that TPA caused the inhibitory effects by means of activating protein kinase C, and suggested that protein kinase C might regulate enzyme secretion by inhibiting calcium mobilization, probably through a postreceptor-mediated mechanism.


Subject(s)
Alkaloids/pharmacology , Amylases/metabolism , Calcium/metabolism , Isoquinolines/pharmacology , Pancreas/metabolism , Piperazines/pharmacology , Protein Kinase C/antagonists & inhibitors , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine , Animals , Carbachol/pharmacology , Cytosol/metabolism , Kinetics , Male , Pancreas/drug effects , Protein Kinase C/metabolism , Rats , Rats, Inbred Strains , Staurosporine , Tetradecanoylphorbol Acetate/pharmacology
17.
Pancreas ; 7(4): 503-6, 1992.
Article in English | MEDLINE | ID: mdl-1641393

ABSTRACT

A 72-year-old man with recurrent pancreatitis and a horseshoe-shaped anomaly of the pancreas is described. The diagnosis was made by endoscopic retrograde cholangiopancreatography (ERCP) and computed tomography scan; laparotomy was confirmatory. The abnormal duct branched to the lower left from an enlarged Santorini's duct; a thin Wirsung's duct was joined at its distal portion to the junction of the abnormal duct. The anomaly was associated with a cystic dilatation of the common bile duct with stone and cholecystolithiasis. This anomaly is considered to be a variation of the dominant dorsal duct syndrome.


Subject(s)
Pancreas/abnormalities , Aged , Cholangiopancreatography, Endoscopic Retrograde , Diagnosis, Differential , Humans , Male , Pancreas/diagnostic imaging , Pancreatic Ducts/abnormalities , Pancreatic Ducts/diagnostic imaging , Pancreatitis/diagnosis , Pancreatitis/diagnostic imaging , Pancreatitis/pathology , Tomography, X-Ray Computed
18.
Melanoma Res ; 10(5): 412-20, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11095401

ABSTRACT

Phorbol esters, which activate protein kinase C, stimulate the growth of normal human melanocytes yet inhibit the growth of most melanoma cells. We investigated whether apoptosis mediates the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) on melanocyte and melanoma cell growth. Few apoptotic cells were present when melanocytes were cultured with TPA. Upon removal of TPA, the number of apoptotic cells increased over 10 days. Addition of TPA did not induce apoptosis in a metastatic melanoma cell line, Demel, although it strongly inhibited its growth. Protection of normal melanocytes from apoptosis was associated with high levels of Bcl-2. Following withdrawal of TPA from melanocytes, the expression of Bcl-2 decreased steadily. Bax and Bcl-X(L) levels did not differ between melanoma cells or melanocytes and were unaffected by the addition of TPA. These results suggest that TPA plays an important role in stimulating the growth of melanocytes by promoting anti-apoptotic mechanisms associated with high levels of Bcl-2.


Subject(s)
Apoptosis/drug effects , Cell Survival/physiology , Melanocytes/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Annexin A5/analysis , Apoptosis/physiology , Cell Survival/drug effects , Cells, Cultured , Humans , Infant, Newborn , Kinetics , Male , Melanocytes/cytology , Melanocytes/physiology , Melanoma/pathology , Proto-Oncogene Proteins/metabolism , Skin/cytology , Time Factors , Tumor Cells, Cultured , bcl-2-Associated X Protein , bcl-X Protein
19.
In Vitro Cell Dev Biol Anim ; 33(9): 717-26, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9358288

ABSTRACT

This study describes the establishment and characterization of an immortalized cell line derived from the pancreas of an adult H-2Kb-tsA58 transgenic mouse. These cells, designated IMPAN for IMmortalized PANcreatic cells, displayed a cobblestone appearance typical of confluent epithelial cells and a distinct polarity in the organization of their cytoplasmic organelles. Immunocytochemical studies revealed that all IMPAN cells stained positively for a wide range of markers characteristic of pancreatic acinar cells, namely the secretory products alpha-amylase, chymotrypsinogen, DNAse, the lectinlike secretory protein PAP (pancreatitis associated protein), and the zymogen granule membrane proteins GP-2 and gp300. They also stained positively for carbonic anhydrase II and cytokeratin 19, two proteins characteristic of pancreatic duct cells, as well as for rab3A, a small GTP-binding protein specifically localized in pancreatic islet cells. No reactivity was ever obtained with insulin antibodies. Taken together, these results show that the IMPAN cells exhibit a phenotype comparable to exocrine pancreatic acinar cells. However the expression of some proteins more specific to duct and islet cells make them similar to in vivo or in vitro growing acinar cells. The cell line should be a valuable model to study the mechanisms of growth, differentiation, and transformation of the exocrine pancreatic acinar cell.


Subject(s)
Pancreas/chemistry , Pancreas/cytology , Animals , Antigens/chemistry , Antigens/immunology , Cell Division , Cell Line, Transformed , Cell Size , Cell Transformation, Viral , Male , Mice , Mice, Transgenic , Microscopy, Immunoelectron , Pancreas/enzymology , Pancreas/ultrastructure , Pancreatitis-Associated Proteins , Staining and Labeling
20.
Int J Pharm ; 233(1-2): 61-6, 2002 Feb 21.
Article in English | MEDLINE | ID: mdl-11897411

ABSTRACT

We developed an intranasal powder form of glucagon to improve metabolic status and fatty liver in patients with pancreatectomy. Microcrystalline cellulose, which is commonly used in commercial preparations for allergic rhinitis was used as an absorption enhancer. We compared the intranasal powder form with some spray solutions of glucagon with regard to glucagon absorption, concentration of blood glucose, stability and nasal irritation. The absorption of glucagon from the spray solution including 1.5% sodium glycocholate or 1% sodium caprate was 1.3- and 2.6-fold higher than that from the powder form mixed with microcrystalline cellulose at a ratio of 1:69, respectively. The C(max) values of plasma glucose were 2.18, 3.39 and 1.56 mmol l(-1) in the spray solutions including sodium glycocholate and sodium caprate and in the powder form, respectively. However, glucagon in spray solutions was unstable, but that in the powder form was stable at 5 and 25 degrees C for at least 84 days. The spray solution caused strong irritation, but the powder form did not. These results suggested usefulness of the powder form of glucagon for treatment of pancreatectomized patients.


Subject(s)
Cellulose/administration & dosage , Drug Delivery Systems/methods , Glucagon/administration & dosage , Administration, Intranasal , Adult , Analysis of Variance , Blood Glucose/metabolism , Chemistry, Pharmaceutical , Drug Stability , Excipients/administration & dosage , Glucagon/blood , Humans , Male , Nebulizers and Vaporizers , Powders , Protein Synthesis Inhibitors/administration & dosage , Protein Synthesis Inhibitors/blood
SELECTION OF CITATIONS
SEARCH DETAIL